Cantor Fitzgerald, Goldman Sachs and Zacks also have a “buy” rating on the stock, according to the report.
AmSurg has a 52-week low of $44.61 and 52-week high of $70.53.
More articles on transactions and valuation issues:
Surgery Center South in Alabama files CON for expansion
New ASC opening at Rockaway Beach: 8 things to know
SurgCenter Development, physicians to open $2M JV surgery center in Ohio: 3 things to know
